Envudeucitinib for Active Systemic Lupus Erythematosus

Envudeucitinib for Active Systemic Lupus Erythematosus
45%34%23%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 38.0%May 28 • YES 29.9%
Alumis Inc ($ALMS)
No stock close$22.52$21.74$20.96May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • ALMS $21.15May 19 • ALMS $21.53May 20 • ALMS $22.04May 21 • ALMS $22.17May 22 • ALMS $22.02May 26 • ALMS $22.33May 27 • ALMS $21.33May 28 • ALMS $21.40

Will this trial show a positive result on proportion of patients with BICLA lupus disease-activity response at Week 48?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
7/1/26
Study Completion
9/1/27
Sponsor
Alumis Inc
Ticker
$ALMS
Type
Phase 2
Trial Status
Active Not Recruiting
Trial Size
408
NCT
NCT05966480
Trial Description
This study tests envudeucitinib in adults with active systemic lupus, measuring overall lupus disease-activity response at 48 weeks.